Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary

Adaptive Biotechnologies

05/08/2025 22:02

Adaptive Biotechnologies Corp ADPT.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -31 cents.  The mean expectation of eight analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -26 cents to -22 cents per share.

Revenue rose 36.3% to $58.88 million from a year ago; analysts expected $49.40 million.

Adaptive Biotechnologies Corp's reported EPS for the quarter was a loss of 17 cents​.

The company reported a quarterly loss of $25.61 million.

Adaptive Biotechnologies Corp shares had fallen by 6.4% this quarter and gained 82.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $12.50, about 12.7% above its last closing price of $10.91

This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.24
-0.17
Beat
Mar. 31 2025
-0.29
-0.20
Beat
Dec. 31 2024
-0.26
-0.23
Beat
Sep. 30 2024
-0.29
-0.22
Beat